Swissmedic agrees closer collaboration in therapeutic products field with Dutch partner authority
Bern, 14.09.2018 - Swissmedic, the Swiss Agency for Therapeutic Products, intends to intensify collaboration with its partner authority in the Netherlands. In Washington on 11 September 2018, Swissmedic Director Raimund Bruhin signed a Memorandum of Understanding (MoU) with Director Hugo Hurts and Chairman Ton de Boer of the Dutch authority, the Medicines Evaluation Board (MEB).
The MoU provides a formal basis for stepping up collaboration and working together on bilateral initiatives. Swissmedic and MEB will be able to benefit from a more intensive bilateral exchange of information. The two authorities are also involved in global multilateral initiatives such as the International Coalition of Medicines Regulatory Authorities (ICMRA). Closer cooperation between Swissmedic and MEB therefore benefits both parties and will help them to accomplish their mission efficiently.
Given the constantly evolving regulatory environment and the ever more global and complex nature of therapeutic product development and production, international collaboration is an important factor in meeting the growing challenges.
In keeping with the mandate conferred on it by the Federal Council, Swissmedic has thus been endeavouring for some years to improve cooperation in the field of therapeutic products with partner authorities abroad. Bilateral networking efforts are focusing primarily on therapeutic products agencies in the EU and countries of strategic interest to Switzerland.
Address for enquiries
Swissmedic, Swiss Agency for Therapeutic Products
Danièle Bersier, Media Spokesperson
+41 58 462 02 76
media@swissmedic.ch
Publisher
Swiss Agency for Therapeutic Products
http://www.swissmedic.ch/?lang=2
